Zymeworks (FRA:ZA8) LT-Debt-to-Total-Asset : 0.04 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Zymeworks LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zymeworks's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.04.

Zymeworks's long-term debt to total assets ratio declined from Mar. 2023 (0.04) to Mar. 2024 (0.04). It may suggest that Zymeworks is progressively becoming less dependent on debt to grow their business.

Zymeworks LT-Debt-to-Total-Asset Historical Data

The historical data trend for Zymeworks's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks LT-Debt-to-Total-Asset Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.08

0.04

Zymeworks Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.04

Zymeworks LT-Debt-to-Total-Asset Calculation

Zymeworks's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	20.597	/	532.667
	=	0.04

Zymeworks's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	19.383	/	509.452
	=	0.04

Zymeworks (FRA:ZA8) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Zymeworks LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Zymeworks's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (FRA:ZA8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ZYME:USA

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines